RxDoctor Payments Data

Mary Boname

Corneal and Contact Management · Skillman, NJNPI 1932132024

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Oyster Point Pharma, Inc. at 39.6% of the total. Reporting peaked in 2023 at $230 and has fallen 85.0% since, to $34 in 2025. That places this record below the midpoint for corneal and contact management clinicians in NJ, where the typical reported total is $1,101.

$574in general payments, 2019–2025

Across 31 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$227
  • Coopervision Inc.$104
  • Rxsight Inc$70
  • Shire North American Group Inc$47
  • Alcon$24
  • Maculogix, Inc.$22
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$55797%
  • Gifts$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$574 in reported general payments places this provider in the 35th percentile of 45 corneal and contact management providers in New Jersey.

See all corneal and contact management providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,036
Medicare patients
228
Services billed
445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine18$31,787
Doxycycline Hyclate29$585
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha18$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$13$31,78718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 45 corneal and contact management providers in New Jersey.

Other corneal and contact management in Skillman

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →